While CTLA-4 inhibitors can be highly effective, they also come with a risk of immune-related adverse events (irAEs). These side effects occur because the enhanced immune response can sometimes attack normal tissues and organs. Common irAEs include colitis, hepatitis, dermatitis, and endocrinopathies. It is crucial for healthcare providers to monitor patients closely and manage these side effects promptly to minimize complications.
